The study and its comparison
SPRING compared a two-species probiotic with placebo from the second trimester in pregnant women with overweight or obesity. The report described 411 completers and assessed gestational diabetes with a glucose-tolerance test. [1]
Diabetes occurred in about eighteen percent of probiotic recipients and twelve percent of controls; the difference was not statistically significant. Selected secondary outcomes, including excessive weight gain, favored probiotics, while fasting glucose was slightly higher. [1]
What the finding establishes
The numerical diabetes difference is not proof of harm, but it clearly does not establish prevention. Multiple secondary outcomes require caution, and the completer count is not necessarily initial enrollment. Funding and conflicts were not established from the abstract. The study tested a specific prevention regimen, not treatment after diagnosis or an isolated GLP-1 mechanism. [1]
A hypothetical distinction
Imagine one secondary outcome improves while the disease-prevention endpoint does not. The main preventive claim remains unsupported.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-Blind Randomized Controlled Trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.